Table 1.

PICOS strategy.

Acronym PICOS	Inclusion Criteria	Exclusion Criteria
P—Population	Patients with high-grade CIN (grade 2/3 associated with HPV)	Patients with associated immunosuppression
I—Intervention	Patients receiving therapeutic vaccines for the treatment of high-grade CIN 2/3 associated with HPV	Use of prophylactic vaccines for the treatment of CIN 2/3 associated with HPV or other neoplasms
C—Control	Patients who received placebo or patients serving as their own control
O—Outcomes	Safety, efficacy, and immunogenicity of therapeutic vaccines used in patients with high-grade CIN 2/3 associated with HPV	Studies that do not report at the same time the three endpoints (safety, efficacy, and immunogenicity)
S—Study Design	RCT or NRCT	Reviews, theses, dissertations, expert opinions, editorials, protocols, clinical guidelines, and conference proceedings